Mercer Global Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mercer Global Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-739	Closed	-$224K	–	3228
2025 Q4	$224K	Sell	739 -13	-2%	-$4.06K	﹤0.01%	2469
2025 Q3	$211K	Buy	+752	New	+$205K	﹤0.01%	2357
2024 Q1	–	Sell	-816	Closed	-$263K	–	2021
2023 Q4	$263K	Buy	+816	New	+$256K	﹤0.01%	1686
2022 Q3	–	Sell	-437	Closed	-$216K	–	1830
2022 Q2	$216K	Buy	+437	New	+$228K	﹤0.01%	1595
2022 Q1	–	Sell	-411	Closed	-$311K	–	1874
2021 Q4	$311K	Sell	411 -58	-12%	-$43.4K	﹤0.01%	1444
2021 Q3	$350K	Sell	469 -158	-25%	-$118K	﹤0.01%	1352
2021 Q2	$404K	Buy	627 +38	+6%	+$23.1K	﹤0.01%	1245
2021 Q1	$336K	Sell	589 -15	-2%	-$8.88K	﹤0.01%	1255
2020 Q4	$352K	Buy	+604	New	+$344K	﹤0.01%	1004

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mercer Global Advisors's BIO Position: Q1 2026 in Review

Mercer Global Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 739 shares — an estimated $224K sold.

Mercer Global Advisors first reported a position in BIO in Q4 2020 and held it in 9 quarters. The position peaked at $404K in Q2 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Mercer Global Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
Mercer Global Advisors sold 739 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $224K.
Mercer Global Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 9 quarters.
Mercer Global Advisors's Bio-Rad Laboratories Class A position peaked at $404K in Q2 2021.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.